Expert Point of View: Winald Gerritsen, MD, PhD


Get Permission

Winald Gerritsen, MD, PhD

Winald Gerritsen, MD, PhD

“This is a really great study with excellent translational research,” said formal discussant Winald Gerritsen, MD, PhD, Professor of Immunotherapy at Radboud University Medical Center, Nijmegen, The Netherlands. “I consider it practice-changing for Merkel cell carcinoma. The company is going for expedited review by the U.S. Food and Drug Administration, and it can be used off-label in some countries.” Other companies are doing studies in Merkel cell carcinoma with similar compounds, continued Dr. Gerritsen.

“Merkel cell carcinoma is a very aggressive disease. We were surprised when responses to pembrolizumab were seen within 2 to 3 months,” he added. ■

Disclosure: Dr. Gerritsen reported no potential conflicts of interest.


Related Articles

Anti–PD-1 Inhibitor Gains Foothold in Merkel Cell Carcinoma

Immunotherapy marches on! One of the latest frontiers for checkpoint inhibitors is the treatment of Merkel cell carcinoma, a rare but aggressive type of cancer.

First-line therapy with pembrolizumab (Keytruda)—an anti–PD-1 (programmed cell death protein 1) inhibitor—achieved an objective response...

Advertisement

Advertisement



;
Advertisement

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.